Primary adenoid cystic carcinoma (basal cell type) of the prostate: a case report Authors: Ruiqi Xie, Tianshu Chu, Jingshu Cui, Jun Jin, Haiyue Chen Published: 2026 ABSTRACT BackgroundProstatic adenoid cystic (basal cell) carcinoma is an extremely rare malignant epithelial neoplasm, accounting for a very low proportion of all prostate malignancies. Its clinical symptoms and imaging features are non-specific, and serum PSA levels are mostly normal or only mildly elevated, posing diagnostic challenges.Case presentationA 46-year-old male presented with progressive hematuria and lower urinary tract obstruction symptoms. His PSA level was not significantly elevated. Imaging revealed a prostatic space-occupying lesion with multiple adjacent small lymph nodes. Histopathological examination of biopsy specimens showed tumor cells arranged in solid nests and cribriform patterns, with hyperchromatic nuclei, uniform morphology, and peripheral palisading. Immunohistochemistry showed positivity for p63 and high-molecular-weight CK, negativity for PSA, and a Ki-67 index of approximately 40%. A diagnosis of primary adenoid cystic (basal cell) carcinoma of the prostate was confirmed.ConclusionThis case highlights the importance of recognizing this rare tumor in patients with prostatic mass and normal PSA, with diagnosis relying on characteristic histomorphology and immunophenotype. Introduction Prostate cancer is one of the most common malignancies in men, with the vast majority being adenocarcinomas originating from the acinar epithelium. However, a rare epithelial tumor, known as adenoid cystic (basal cell) carcinoma, can also occur in the prostate. This tumor is postulated to originate from the basal cells of the prostatic ducts or acini. Its histological morphology, immunophenotype, and biological behavior are distinct from those of conventional prostatic adenocarcinoma. This tumor is extremely rare in clinical practice, with most reports being limited to case reports or small case series. Due to its low incidence and insufficient awareness, diagnosis is often delayed or incorrect. Patients typically present with symptoms of lower urinary tract obstruction or hematuria, which are similar to those of benign prostatic hyperplasia or other types of prostate cancer. A key distinguishing feature is that serum prostate-specific antigen (PSA) levels are normal or only mildly elevated in the vast majority of cases, consistent with the biological characteristic that these tumor cells do not express PSA. Imaging findings are non-specific, often showing a prostatic mass that may be associated with local invasion or lymph node metastasis. Therefore, definitive diagnosis relies heavily on histopathological examination and characteristic immunophenotyping. Currently, the World Health Organization (WHO) Classification of Tumours, 5th edition, categorizes it as an independent type of prostatic epithelial tumor—a basal cell carcinoma. Its biological behavior is heterogeneous; some cases follow an indolent course, while others exhibit significant local aggressiveness and potential for distant metastasis. Due to the limited number of reported cases, an optimal treatment regimen has not been established. Clinical management often draws upon the multidisciplinary comprehensive treatment model used for high-risk prostate cancer. By reporting a pathologically confirmed case and reviewing the latest literature, this paper aims to systematically discuss the clinicopathological characteristics, diagnostic approach, and therapeutic advancements for this tumor, thereby improving clinical understanding and management of the disease. Epidemiology Primary prostatic adenoid cystic (basal cell) carcinoma is exceptionally rare, accounting for less than 0.1% of all prostate malignancies. To date, approximately 50 cases have been reported in the English literature. The mean age at diagnosis is 64 years (range 36–86 years). Serum PSA levels are normal in more than 90% of reported cases, reflecting the lack of PSA expression by basaloid tumor cells. Patient information Age: 46 years. Sex: Male. Primary concerns: Progressive gross hematuria, frequent urination, urgency, dysuria for 3 months. Medical history: No significant past medical history. Family history: No family history of prostate cancer. Psychosocial history: Not reported. Relevant past interventions: None. Clinical findings Vital signs: Stable. Digital rectal examination (DRE): Enlarged prostate (grade III), irregular surface, multiple palpable hard nodules, ill-defined borders, no tenderness. Other findings: No fever, no low back pain, no significant weight loss. Timeline Date (2025) Event. July: Admission with progressive hematuria and lower urinary tract symptoms. July: Digital rectal examination, serum PSA (normal), CT scan (prostatic mass + pelvic lymph nodes). July: Transrectal ultrasound-guided prostate biopsy (2 cores). July: Pathological examination and immunohistochemistry. July: Diagnosis confirmed: Adenoid cystic (basal cell) carcinoma. Diagnostic assessment Diagnostic methods Laboratory Serum total PSA (< 4.0 ng/mL, normal); free-to-total PSA ratio (normal); complete blood count and liver/kidney function tests (normal). Imaging CT scan showed a prostatic mass involving the right wall of the urinary bladder and the terminal segment of the right ureter, with multiple small pelvic lymph nodes. Biopsy Systematic transrectal ultrasound-guided prostate biopsy with targeted needles (2 core specimens). Pathological findings Gross: Two gray-white tissue cores, each approximately 1.5 cm in length. Light microscopy: Tumor cells arranged in solid nests and cribriform patterns infiltrating the prostatic stroma (Fig. 1A, B); basophilic or eosinophilic basement membrane-like material within cribriform spaces; uniform tumor cells with oval to spindle-shaped nuclei, hyperchromatic chromatin, inconspicuous nucleoli; peripheral palisading arrangement; desmoplastic stromal reaction. Notably, due to the limited sampling of needle core biopsy, no definitive perineural invasion was identified. Immunohistochemistry: p63 (diffuse strong nuclear positivity), high-molecular-weight CK (diffuse strong cytoplasmic positivity), PSA (negative), GATA3 (negative), synaptophysin (negative), chromogranin A (negative); Ki-67 proliferation index approximately 40% (Fig. 1C-F). Diagnostic challenges: Non-specific symptoms, normal PSA, imaging findings similar to benign prostatic hyperplasia or other prostate cancers. Diagnosis: Primary adenoid cystic (basal cell) carcinoma of the prostate. Differential diagnoses considered: Conventional prostatic adenocarcinoma (PSA positive, basal marker negative). Urothelial carcinoma involving the prostate (GATA3+, p40+, CK7+/CK20+) — excluded by negative GATA3. Prostatic basal cell hyperplasia (lobulated, multifocal, no significant cytologic atypia). Prognostic characteristics: High Ki-67 (40%), local invasion (bladder wall, ureter), pelvic lymphadenopathy — suggests aggressive biological behavior. Therapeutic intervention Type of intervention: No therapeutic intervention was administered in this case report as the focus was on diagnosis. The patient was referred for multidisciplinary discussion. Follow-up and outcomes Clinician- and patient-assessed outcomes: Not reported in this case. Important follow-up diagnostic results: Not reported. Intervention adherence and tolerability: Not applicable. Adverse and unanticipated events: None reported. Diagnosis (Prostate biopsy tissue) Adenoid cystic (basal cell) carcinoma. Fig. 1A Classic histological morphology of basal cell carcinoma of the prostate (HE, ×200). B Diffuse growth pattern of basal cell carcinoma of the prostate (HE, ×200). C Tumor cells showing diffuse positivity for p63 (IHC, ×200). D Tumor cells showing diffuse positivity for CK (IHC, ×200). E High expression of Ki-67 in tumor cells (approximately 40%) (IHC, ×200). F Tumor cells negative for PSA (IHC, ×200). G Tumor cells negative for GATA3 (IHC, ×200) A Classic histological morphology of basal cell carcinoma of the prostate (HE, ×200). B Diffuse growth pattern of basal cell carcinoma of the prostate (HE, ×200). C Tumor cells showing diffuse positivity for p63 (IHC, ×200). D Tumor cells showing diffuse positivity for CK (IHC, ×200). E High expression of Ki-67 in tumor cells (approximately 40%) (IHC, ×200). F Tumor cells negative for PSA (IHC, ×200). G Tumor cells negative for GATA3 (IHC, ×200) Discussion Primary adenoid cystic (basal cell) carcinoma of the prostate is a malignant tumor with distinct pathological characteristics. The cornerstone of its diagnosis lies in recognizing characteristic histomorphology supported by confirmatory immunophenotyping [1]. Histopathological Features: The tumor exhibits a variety of architectural patterns, including solid, trabecular, cribriform, tubular, and adenoid cystic structures, often present in combination [2]. The classic adenoid cystic carcinoma-like areas, reminiscent of its salivary gland counterpart, are composed of basaloid cells surrounding eosinophilic or basophilic mucoid or hyaline basement membrane-like material [3]. Nuclear morphology is relatively uniform, with fine chromatin and inconspicuous nucleoli, although nucleoli can be prominent in some cases [4]. A peripheral palisading arrangement is an important morphological clue. It is essential to differentiate this entity from other basaloid lesions of the prostate, such as basal cell hyperplasia and other tumors in the basal cell tumor spectrum [5]. Immunophenotypic Characteristics: Immunohistochemistry is crucial for diagnosis and differential diagnosis. Tumor cells consistently express basal cell markers, such as p63, CK5/6, CK14, and high-molecular-weight cytokeratins (e.g., CK903). In contrast, markers of prostatic acinar differentiation, including prostate-specific antigen (PSA), prostatic acid phosphatase (PAP), and androgen receptor (AR), are typically negative or only focally and weakly positive. This immunophenotype is the inverse of that seen in conventional prostatic adenocarcinoma. In the present case, strong positivity for p63 and high-molecular-weight CK, along with negative PSA and GATA3 staining, aligns with the typical phenotype of this tumor and effectively rules out urothelial carcinoma. The Ki-67 proliferation index is highly variable, and a high index may indicate more aggressive biological behavior. Differential Diagnosis: The main differential diagnoses include: (1) Conventional prostatic adenocarcinoma, particularly the solid or ductal subtypes, which are PSA-positive and basal marker-negative. (2) Urothelial carcinoma involving the prostate, which typically expresses GATA3, p40, and high-molecular-weight cytokeratins. In this case, negative GATA3 staining effectively ruled out urothelial carcinoma. (3) Prostatic basal cell hyperplasia and other basaloid tumors. Benign basal cell hyperplasia is usually lobulated, multifocal, and lacks significant cytologic atypia. Atypical basal cell hyperplasia and basal cell adenoma/carcinoma share morphological overlap with this entity, sometimes making distinction challenging; they are occasionally considered part of a spectrum of the same disease with different grades or morphological subtypes. PSMA Expression and Theranostic Implications: PSMA expression in prostatic basal cell carcinoma remains poorly characterized. Based on the basal cell phenotype and negative PSA staining, PSMA expression is expected to be low to absent. In the present case, PSMA PET/CT was not performed. Consequently, lutetium-177 (^177^Lu)-PSMA radioligand therapy is unlikely to be beneficial for this tumor type. Future studies investigating PSMA expression in prostatic ACC are warranted. Treatment Modalities: Due to the rarity of this entity, no standardized treatment protocol exists. Based on available literature and experience with salivary gland ACC, the following approaches have been employed: Radiotherapy: For locally advanced or incompletely resected disease, conventional fractionation regimens (e.g., 66–70 Gy in 33–35 fractions) are typically used. Chemotherapy: In metastatic or recurrent cases, platinum-based regimens have shown anecdotal efficacy, such as carboplatin (AUC 5–6) plus paclitaxel (175 mg/m²) every 3 weeks. Targeted therapy: EGFR inhibitors (cetuximab, gefitinib) and tyrosine kinase inhibitors (lenvatinib, sorafenib) have been investigated in salivary ACC with limited activity; their role in prostatic ACC remains undefined. Clinical Management and Prognosis: The biological behavior of this tumor is heterogeneous and difficult to predict. Some cases follow an indolent course akin to low-grade malignancies. However, increasing reports indicate potential for local aggressiveness, with invasion into adjacent structures such as the seminal vesicles, bladder, or rectum, and a risk of lymph node and distant metastasis. In this case, involvement of the seminal vesicles and the presence of pelvic lymphadenopathy indicate aggressive disease. There is currently no standard treatment regimen. For localized disease, radical prostatectomy is the primary option. For locally advanced or high-risk cases, a multimodal approach combining surgery with adjuvant radiotherapy is often employed. As these tumors typically lack androgen receptor expression, conventional androgen deprivation therapy is of uncertain benefit but may be considered in advanced palliative settings. Platinum-based chemotherapy regimens have shown some efficacy in metastatic cases. Therefore, a multidisciplinary team approach is crucial for optimal management. Suggested treatment approach based on literature review Although a formal MDT outcome was not available for this case, based on the existing literature [1–5], the following approach is recommended for similar cases: Localized disease: Radical prostatectomy with pelvic lymph node dissection is the preferred treatment. Locally advanced or positive margins: Adjuvant radiotherapy (66 Gy in 33 fractions) should be considered. Metastatic disease: Platinum-based chemotherapy (carboplatin + paclitaxel) is a reasonable option. PSMA-targeted therapy: Not recommended due to expected low PSMA expression. Surveillance: Should rely on imaging (CT/MRI) rather than PSA, as PSA is not a reliable biomarker for this tumor. Limitations This study has several limitations. First, due to the limited tissue available from needle core biopsy and the fact that comprehensive genomic profiling (CGP/NGS/FISH) is not routinely performed at our institution, molecular testing for MYB::NFIB fusion, PTEN loss, or EGFR overexpression was not conducted. Second, PSMA PET/CT was not performed; therefore, PSMA expression status in this tumor remains unknown. Third, as this is a retrospective case report focusing on diagnosis, long-term follow-up and MDT treatment outcomes are not available. Fourth, perineural invasion was not identified, which may be attributable to the limited sampling of core biopsy. Conclusion Primary adenoid cystic (basal cell) carcinoma of the prostate is a rare malignancy with well-defined pathological features. Clinicians should maintain a high index of suspicion in patients with significant prostatic masses disproportionate to serum PSA levels. Pathological diagnosis relies on characteristic cribriform/basaloid morphology and an immunophenotype that is positive for p63/cytokeratin and negative for PSA. This tumor possesses invasive potential, necessitating individualized treatment. Management should be based on radical surgery, potentially combined with radiotherapy, chemotherapy, and other modalities within a multidisciplinary framework. Enhancing awareness of this disease can facilitate earlier and more accurate diagnosis, leading to the development of appropriate treatment strategies and potentially improving patient outcomes. Future studies involving larger case series and molecular investigations are needed to further elucidate its pathogenesis and explore more effective therapeutic options.